Try GOLD - Free

Cafeteria Diet - One of the prominent reasons behind stroke in India

Bio Spectrum

|

December 2016

In the recently concluded 10th World Stroke Congress 2016 at Hyderabad, jointly organised by World Stroke Organisation (WSO) and Indian Stroke Association & Medtronic Inc., medical practitioners announced the launch of Stroke Roadmap in India. Currently, stroke incidence in India is much higher than western industrialised countries. With a population of 1.2 billion today and growing, India finds itself staring at a stroke epidemic.

The officials claim that the newly designed roadmap is intended to guide local healthcare officials and stroke care clinical groups in establishing stroke systems of care and will provide the framework for the implementation, monitoring and evaluation of stroke services nationally. In an exclusive interaction with BioSpectrum, Dr Jeyaraj Durai Pandian, Head of Neurology, Christian Medical College and Hospital, Ludhiana elaborates on the subject, and how the Stroke Roadmap might prove a perfect shield to dodge the disease.

- Nitin Konde

Cafeteria Diet - One of the prominent reasons behind stroke in India

Dr. Jeyaraj Durai Pandia

Head of Neurology, Christian Medical College and Hospital, ludhiana

Q: Why is the stroke rate climbing in India, specifically among the young generations?

A: 1.8 million Indians out of a population of 1.2 billion suffer from stroke every year. Common risk factors such as hypertension, diabetes, smoking, and dyslipidaemia are prevalent and insufficiently controlled due to low awareness levels of the disease. One of the primary factors of early stroke is the so-called ‘cafeteria diet’ which is rich in high-calorie, high-sugar and high-salt foods. Smoking and uncontrolled alcohol consumption also serve to exacerbate the situation.

The rising incidence of stroke in India indicates the inadequate levels of awareness and education about the disease. A stroke can strike anyone, at any time. Stroke rates among young and middle-aged people nationwide are increasing, almost 15 to 20 percent of strokes occur in people in their 30s and 40s.

Q: What is the general perception of the denizens of the country regarding stroke?

A: Surveys conducted over the last ten years reveal that about one-fourth of urban and one-third of rural respondents had no knowledge of any warning symptoms of stroke. Only 55 percent of the urban population were aware of one warning symptom of stroke; 16.2 percent were aware of two symptoms; and only 6.2 per cent could identify three symptoms.

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally

Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency

India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.

time to read

10 mins

November 2025

Bio Spectrum

When Spectra Speak: Letting AI Read the Fine Print of Biologics

Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.

time to read

5 mins

November 2025

Bio Spectrum

Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale

Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;

time to read

4 mins

November 2025

Bio Spectrum

Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad

Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.

time to read

1 min

November 2025

Bio Spectrum

Patient Consent - How is it different under medical ethics and data protection?

In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation

An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

Abbott launches world's first dual-chamber leadless pacemaker system in India

Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.

time to read

1 min

November 2025

Bio Spectrum

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

November 2025

Translate

Share

-
+

Change font size